This multi-cohort phase II study evaluated the efficacy and safety of nivolumab combined with abemaciclib and fulvestrant or letrozole as a first-line/second-line treatment for HR+/HER2− advanced breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.